Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
CHO PharmaROCO:6586 -4.57%31 EV-to-EBIT is -76.23 as of Sep. 04, 2026. GuruFocus rates ROCO:6586 with a GF Score™ of 31/100. The stock has 2 warning signs investors should review. Among 368 Biotechnology companies, CHO Pharma ranks worse than 271738.86% on this metric.
This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.
CHO Pharma's Enterprise Value for the quarter that ended in Jun. 2026 was NT$26,403.53 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. CHO Pharma's EBIT for the trailing twelve months (TTM) ended in Jun. 2026 was NT$-267.77 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
CHO Pharma EV-to-EBIT Related Terms
CHO Pharma EV-to-EBIT Historical Data
* Premium members only.
The historical data trend for CHO Pharma's EV-to-EBIT can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ROCO:6586 vs VRTX, REGN, MRNA: EV-to-EBIT Comparison
For the Biotechnology subindustry, CHO Pharma's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
CHO Pharma EV-to-EBIT vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, CHO Pharma's EV-to-EBIT distribution charts can be found below:
* The bar in red indicates where CHO Pharma's EV-to-EBIT falls into.
CHO Pharma's current Enterprise Value is NT$20,411.17 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. CHO Pharma's EBIT for the trailing twelve months (TTM) ended in Jun. 2026 was NT$-267.77 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
CHO Pharma (ROCO:6586) has a EV-to-EBIT of -76.23 as of Sep. 04, 2026. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on CHO Pharma and its competitors. According to the industry distribution chart, CHO Pharma ranks #999999 out of 368 companies in the Biotechnology industry.
Is CHO Pharma's EV-to-EBIT too high?
CHO Pharma's current EV-to-EBIT is -76.23. Based on the distribution chart, CHO Pharma ranks #999999 out of 368 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, CHO Pharma has a GF Score™ of 31/100, reflecting its overall financial health beyond just this single metric.
How does CHO Pharma's EV-to-EBIT compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, CHO Pharma ranks #999999 out of 368 companies for EV-to-EBIT. This places CHO Pharma in the lower half of its industry. The industry median EV-to-EBIT is 15.55. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBIT for a Biotechnology company?
The median EV-to-EBIT among Biotechnology companies is 15.55, based on 368 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBIT significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBIT mean?
A high EV-to-EBIT can signal that a stock is expensive relative to its fundamentals. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on CHO Pharma and its competitors. For the Biotechnology industry, the median EV-to-EBIT is 15.55 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. CHO Pharma's current EV-to-EBIT is -76.23. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is CHO Pharma stock overvalued right now?
CHO Pharma (ROCO:6586) has a current EV-to-EBIT of -76.23. The current EV-to-EBIT is -76.23. CHO Pharma's overall GF Score™ is 31/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBIT calculated?
EV-to-EBIT is calculated from a company's financial statements. For CHO Pharma (ROCO:6586), the current EV-to-EBIT is -76.23 as of Sep. 04, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
CHO Pharma Inc is a biopharmaceutical company mainly focused on the development and commercialization of innovative products based on the proprietary glycan engineering technologies. It offers antibodies, such as CHO-H01, CHO-H02, CHO-A04 for cancer; CHO-H03, an antibody for autoimmune disease; CHO-S05 dual-effect anti-flu drugs; and CHO-V06 glycan-based vaccines and drugs.
31GF Score
Get the complete analysis for ROCO:6586
EV-to-EBIT is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ROCO:6586 has been successfully added to your 
